Bottom line
FHLC vs RYHIX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 80% by weight.
But FHLC is far broader, holding 337 positions to 135 for RYHIX, so beyond the top names it adds exposure RYHIX doesn't have.
FHLC is cheaper at 0.084% vs 1.38% — a difference of $130 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +5.1% for RYHIX (reporting dates differ).
Updated Nov 19, 2026
FHLC vs RYHIX side by side
| FHLC | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 1.38% |
| Annual cost per $10k | $8.4 | $138 |
| 10-yr cost on $10k (prospectus) | $108 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +14.4% |
| 5-yr return (annualized) | +7.2% | +5.1% |
| 10-yr return (annualized) | +8.8% | +7.9% |
| Best quarter | +16.4% | +18.7% |
| Worst quarter | −13.1% | −14.4% |
| Net assets (fund) | $3.3B | $19.4M |
| Number of holdings | 337 | 135 |
| Portfolio turnover | 3% | 244% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | RYHIX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +0.6% | +2.0% |
| 2023 | +2.5% | +5.8% | −3.4% |
| 2022 | −5.5% | −11.6% | +6.2% |
| 2021 | +20.4% | +19.2% | +1.1% |
| 2020 | +18.1% | +18.9% | −0.8% |
| 2019 | +21.9% | +22.8% | −0.8% |
| 2018 | +5.5% | +1.6% | +4.0% |
| 2017 | +23.3% | +23.5% | −0.2% |
| 2016 | −3.3% | −9.4% | +6.0% |
Source: Fund prospectus bar charts
Holdings overlap
23 of FHLC's top 25 holdings also appear in RYHIX's top 25.
| Holding | FHLC | RYHIX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 3.63% |
| Johnson & Johnson | 8.93% | 2.88% |
| AbbVie Inc | 6.42% | 2.52% |
| UnitedHealth Group Inc | 5.44% | 2.22% |
| Merck & Co Inc | 4.66% | 2.04% |
| Thermo Fisher Scientific Inc | 3.09% | 1.61% |
| Amgen Inc | 3.00% | 1.56% |
| Abbott Laboratories | 2.66% | 1.42% |
| Gilead Sciences Inc | 2.34% | 1.39% |
| Pfizer Inc | 2.06% | 1.25% |
| Bristol-Myers Squibb Co | 1.93% | 1.22% |
| CVS Health Corp | 1.92% | 1.31% |
| Intuitive Surgical Inc | 1.82% | 1.31% |
| Danaher Corp | 1.80% | 1.30% |
| Vertex Pharmaceuticals Inc | 1.76% | 1.34% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between FHLC and RYHIX?
Which is cheaper, FHLC or RYHIX?
Should I own both FHLC and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.